Premium
Relationship between androgen receptor binding activity in human prostate cancer and clinical response to endocrine therapy
Author(s) -
Benson Ralph C.,
Gorman Paul A.,
O'Brien Peter C.,
Holicky Eileen L.,
Veneziale Carlo M.
Publication year - 1987
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19870501)59:9<1599::aid-cncr2820590913>3.0.co;2-v
Subject(s) - prostate cancer , medicine , androgen receptor , endocrine system , prostate , oncology , hormone , hormonal therapy , cancer , androgen , hormone therapy , endocrinology , breast cancer
The authors investigated the ability of androgen receptor binding in prostate cancer tissue to predict the response of prostate cancer patients to endocrine therapy. The clinical response of 37 previously untreated patients with various grades and stages of prostate cancer was correlated with androgen receptor binding and detailed histologic data obtained before treatment. All patients underwent cold‐punch transurethral resection of the prostate and received endocrine therapy. The association between time to progression and cytosolic androgen binding was not significant. However, the associations of time to progression to nuclear binding and to total androgen binding were significant ( P = 0.029 and 0.038, respectively). The authors found no association between clinical stage and time to progression, but did find an association between time to progression and pathologic grade ( P = 0.003); grade 4 lesions were the least responsive to hormone therapy. When grade 4 lesions were excluded (N = 3), binding levels were still predictive of progression independently of grade and stage. The authors conclude that nuclear receptor binding activity in localized and metastatic prostate cancer tissue is predictive of response to hormonal manipulation.